Top Markets
Coin of the day
Faes Farma, S.A. Faes Farma, S.A.

Faes Farma, S.A.

FAE
Rank in Stocks #7176
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research,... Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
Share Price
$5.42
Last synced: 2026-08-27
Market Cap
$1.69B
Change (1 day)
0.55%
Change (1 year)
10.03%
Country
ES
Trade Faes Farma, S.A. (FAE)

Category

P/B ratio for Faes Farma, S.A. (FAE)
P/B ratio as of 2026 TTM: 0
According to Faes Farma, S.A. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Faes Farma, S.A. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors